The Lancet Rheumatology, published by Elsevier, is a premier academic journal dedicated to advancing the understanding of rheumatology and immunological diseases. Launched in 2019, this esteemed publication has quickly become a leading source of research, achieving an impressive Q1 ranking in both the fields of Rheumatology and Immunology as of 2023. With Scopus rankings placing it at #2 out of 73 in Medicine - Rheumatology and #6 out of 233 in Medicine - Immunology and Allergy, the journal serves as an essential platform for disseminating high-quality, peer-reviewed articles that address the latest findings and clinical practices in these domains. The journal, accessible in print and online, is committed to fostering knowledge and collaboration among researchers, healthcare professionals, and students alike, making it an invaluable resource for those seeking to deepen their expertise in rheumatology and its interrelated fields.

Advances in Rheumatology is a premier open-access journal published by BMC, dedicated to advancing the field of rheumatology through high-quality, peer-reviewed research. Launched in 2018, the journal has quickly established itself within the academic community, achieving a commendable Q2 ranking in the category of Rheumatology as of 2023 and ranking #34 out of 73 in the Scopus Medicine Rheumatology listings, placing it in the 54th percentile. With a focus on innovative treatments, patient care, and the latest in rheumatological research, the journal provides a platform for researchers and clinicians to disseminate their findings and foster collaborative advancements in this critical area of medicine. Recognized for its accessibility, the journal follows an open-access model, ensuring that research is freely available to a global audience. With a commitment to high standards of academic rigor, Advances in Rheumatology plays a vital role in enhancing the understanding and treatment of rheumatic diseases, making it an invaluable resource for researchers, professionals, and students alike.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, published by Wiley, is a premier scholarly journal in the fields of gastroenterology, hepatology, and pharmacology. With an impressive impact factor and ranking in the top quartile (Q1) of its classifications, the journal is recognized for its rigorous peer-reviewed research and comprehensive reviews, aiming to advance the understanding of therapeutic interventions in gastrointestinal and liver diseases. Since its inception in 1987, it has become an essential resource for researchers, healthcare professionals, and students alike, fostering scientific dialogue and innovation. With a Scopus rank placing it in the 97th percentile for pharmacology and 96th for gastroenterology, it is dedicated to publishing the most significant and impactful findings in the field. ALIMENTARY PHARMACOLOGY & THERAPEUTICS thus plays a vital role in shaping the future of medical treatments and interventions in gastrointestinal health.

Welcome to the Indian Journal of Rheumatology, a premier scholarly platform dedicated to advancing research and clinical practice in the field of rheumatology. Published by SAGE Publications Inc., this journal has been providing open access to its valuable content since 2006, promoting the dissemination of knowledge in India and beyond. As a voice in the rheumatology community, the journal addresses a wide range of topics including epidemiology, diagnostics, treatment strategies, and patient care in rheumatic diseases. Despite being classified in the Q4 category of the 2023 Scopus rankings, with a current position of Rank #57 among 73 journals, it serves as an essential resource for researchers, healthcare professionals, and students seeking to stay updated with the latest developments. The journal is committed to fostering scholarly dialogue and facilitating access to research that influences practice and improves patient outcomes in rheumatologic care.

SEMINARS IN ARTHRITIS AND RHEUMATISM, published by W B Saunders Co-Elsevier Inc, is a leading journal in the fields of rheumatology and pain medicine. With an impressive impact factor and recognized as a Q1 journal in both its categories, it ranks #8 in Anesthesiology and Pain Medicine and #11 in Rheumatology based on the latest Scopus data, placing it within the top echelons of academic research. Established in 1971, this esteemed publication offers a comprehensive platform for researchers and practitioners to disseminate and engage with cutting-edge studies that advance the understanding and treatment of arthritis and related conditions. With its robust editorial process and focus on high-quality, peer-reviewed articles, the journal not only contributes to scientific knowledge but also serves as an essential resource for professionals and students seeking contemporary insights into effective management strategies and emerging therapies in the rheumatologic field. Although it does not offer open access, its subscription model ensures a wide distribution among academic and clinical institutions, reinforcing its significance in the research community.

Gastrointestinal Disorders is a prominent open-access journal published by MDPI, based in Switzerland, that focuses on the latest research and innovations in the fields of gastroenterology, hepatology, and immunology. Since its inception in 2019, the journal has provided a vital platform for researchers and professionals to disseminate their findings, engaging with a global audience keen on advancing knowledge in gastrointestinal health. With a dedicated commitment to high-quality, peer-reviewed articles, Gastrointestinal Disorders has gained recognition in 2023, achieving Q3 status in gastroenterology and notable rankings in several other categories, including a respectable position in the quartiles for hepatology, immunology, and oncology. Despite its recent establishment, the journal has quickly become a valuable resource, facilitating open access to critical insights in the study of gastrointestinal diseases and their management, ensuring that emerging research is readily available to inform clinical practice and educate future professionals.

ZEITSCHRIFT FUR RHEUMATOLOGIE, published by Springer Heidelberg, serves as a vital platform in the field of rheumatology, providing researchers, clinicians, and students with cutting-edge findings and discussions related to the diagnosis, treatment, and management of rheumatic diseases. Since its inception in 1974 and continuing until 2024, this journal retains its commitment to disseminating significant scientific work within this specialized domain. Although it is currently categorized in the Q4 quartile for Rheumatology and ranks 47 out of 73 in Scopus, reflecting its burgeoning presence, the journal is dedicated to evolving and gaining prominence in the academic community. By offering valuable insights and fostering scholarly discourse, ZEITSCHRIFT FUR RHEUMATOLOGIE plays a crucial role in advancing rheumatology research and enhancing patient care practices worldwide. The journal presents an opportunity for its readers to engage with contemporary studies and enrich their understanding of rheumatic ailments.

RHEUMATOLOGY, published by Oxford University Press, is a leading journal in the fields of Pharmacology and Rheumatology, recognized for its significant contribution to advancing the understanding and treatment of rheumatic diseases. With an impressive impact factor and ranking within the top quartiles for both medical pharmacology and rheumatology, this journal serves as an essential resource for researchers, clinicians, and healthcare professionals. The journal spans an extensive publication history, with contributions from 1952 to 1995 and from 1998 to 2024, reflecting its enduring commitment to disseminating high-quality research. The Open Access option allows for broader dissemination of knowledge, enhancing the visibility of groundbreaking studies. Positioned in the United Kingdom, RHEUMATOLOGY not only offers valuable insights into the latest therapeutic advancements and clinical guidelines but also fosters collaboration across disciplines, ensuring that practitioners stay at the forefront of innovation in the management of rheumatic conditions.

Modern Rheumatology is a premier journal dedicated to advancing the field of rheumatology through high-quality peer-reviewed research. Published by Oxford University Press, this journal reflects the latest developments in rheumatologic medicine, catering to researchers, clinicians, and students alike. With an H-Index highlighting its scholarly impact, Modern Rheumatology occupies a notable position, ranking Q2 in both the fields of Medicine and Rheumatology in 2023, and is listed among the top 25 journals in its category by Scopus. Spanning from the year 2000 to 2024, the journal features a diverse array of topics aimed at addressing current challenges and innovations in the field. Although it does not offer Open Access, it provides essential insights for professionals seeking to stay abreast of evolving treatment modalities and research breakthroughs. Located in the heart of the United Kingdom, Modern Rheumatology is a vital resource for anyone committed to enhancing the understanding and treatment of rheumatic diseases.

Journal of Rheumatic Diseases, published by the Korean College of Rheumatology, stands as a pivotal platform in the field of rheumatology, contributing significantly to the advancement of knowledge and clinical practice since its inception. With an impact factor reflecting its esteemed position in the academic community, this open-access journal promotes accessibility to high-quality research, ensuring that groundbreaking discoveries are reachable to all stakeholders in the realm of rheumatic diseases. The journal has maintained its commitment to quality, evidenced by its ranking in the Q3 category for Rheumatology in 2023, and its presence among the top quartiles of medical research. Focusing on innovative therapeutic approaches, emerging diagnostic techniques, and comprehensive reviews, the Journal of Rheumatic Diseases seeks to foster collaboration and dialogue among researchers, clinicians, and students alike. For accessibility, the journal offers numerous articles since its transition to open access in 2017, thereby facilitating research dissemination across the globe. As it converges over the years from 2019 to 2024, the journal promises to be instrumental in shaping the future of rheumatic disease research, inviting contributions that inspire new frontiers in this essential field.